Ströhlein MA - Search Results

1

Clinical efficacy of cytoreductive surgery and hyperthermic chemotherapy in peritoneal carcinomatosis from gastric cancer.

Ströhlein MA, Bulian DR, Heiss MM. Ströhlein MA, et al. Expert Rev Anticancer Ther. 2011 Oct;11(10):1505-8. doi: 10.1586/era.11.147. Expert Rev Anticancer Ther. 2011. PMID: 21999124

2

Immunotherapy of peritoneal carcinomatosis.

Ströhlein MA, Heiss MM. Ströhlein MA, et al. Cancer Treat Res. 2007;134:483-91. doi: 10.1007/978-0-387-48993-3_33. Cancer Treat Res. 2007. PMID: 17633076 Review.

3

Comparison of laparoscopic vs. open access surgery in patients with rectal cancer: a prospective analysis.

Ströhlein MA, Grützner KU, Jauch KW, Heiss MM. Ströhlein MA, et al. Dis Colon Rectum. 2008 Apr;51(4):385-91. doi: 10.1007/s10350-007-9178-z. Epub 2008 Jan 25. Dis Colon Rectum. 2008. PMID: 18219531

4

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.

Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM. Ströhlein MA, et al. J Exp Clin Cancer Res. 2009 Feb 14;28(1):18. doi: 10.1186/1756-9966-28-18. J Exp Clin Cancer Res. 2009. PMID: 19216794 Free PMC article. Clinical Trial.

5

Intraperitoneal immunotherapy to prevent peritoneal carcinomatosis in patients with advanced gastrointestinal malignancies.

Ströhlein MA, Heiss MM. Ströhlein MA, et al. J Surg Oncol. 2009 Sep 15;100(4):329-30. doi: 10.1002/jso.21338. J Surg Oncol. 2009. PMID: 19697440 Review.

6

The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.

Ströhlein MA, Heiss MM. Ströhlein MA, et al. Future Oncol. 2010 Sep;6(9):1387-94. doi: 10.2217/fon.10.111. Future Oncol. 2010. PMID: 20919824 Review.

7

[Pleural effusions and ascites--surgical and palliative aspects].

Ströhlein MA. Ströhlein MA. Zentralbl Chir. 2010 Dec;135(6):508-15. doi: 10.1055/s-0030-1262681. Epub 2010 Dec 13. Zentralbl Chir. 2010. PMID: 21154207 Review. German.

8

Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial.

Ströhlein MA, Lordick F, Rüttinger D, Grützner KU, Schemanski OC, Jäger M, Lindhofer H, Hennig M, Jauch KW, Peschel C, Heiss MM. Ströhlein MA, et al. Onkologie. 2011;34(3):101-8. doi: 10.1159/000324667. Epub 2011 Feb 18. Onkologie. 2011. PMID: 21358214 Clinical Trial.

9

Peritoneal carcinomatosis: cytoreductive surgery and HIPEC--overview and basics.

Brücher BL, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, Gonzalez-Moreno S, Pelz J, Königsrainer A, Ströhlein M, Levine EA, Morris D, Bartlett D, Glehen O, Garofalo A, Nissan A. Brücher BL, et al. Cancer Invest. 2012 Mar;30(3):209-24. doi: 10.3109/07357907.2012.654871. Cancer Invest. 2012. PMID: 22360361 Review.

10

Relative lymphocyte count is a prognostic parameter in cancer patients with catumaxomab immunotherapy.

Ströhlein MA, Lefering R, Bulian DR, Heiss MM. Ströhlein MA, et al. Med Hypotheses. 2014 Mar;82(3):295-9. doi: 10.1016/j.mehy.2013.12.014. Epub 2013 Dec 27. Med Hypotheses. 2014. PMID: 24411128

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results